FHTX — Foghorn Therapeutics Share News
0.000.00%
Last trade - 00:00- $118.77m
- -$48.81m
- $30.91m
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Foghorn plunges after scrapping Lilly-backed drug program
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
NASDAQ RESUMED AT 07:30 AM
Brief: Foghorn Therapeutics Expects To Have About 65 Full-Time Employees After Reduction
Brief: Foghorn Therapeutics Provides Update On Fhd-909 And Strategic Priorities
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Foghorn Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Foghorn Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Foghorn Therapeutics Inc - On Dec 3, Appointed Jeff Sacher As Interim CFO - SEC Filing
Brief: Foghorn Therapeutics Inc - On Oct 31, Kristian Humer Resigned As CFO Effective November 14, 2025 - SEC Filing
Foghorn Therapeutics Q3 collaboration revenue rises, net loss narrows on Lilly partnership
Brief: Foghorn Therapeutics Q3 EPS USD -0.25
Foghorn Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Foghorn Therapeutics Q2 collaboration revenue rises, loss narrows
Foghorn Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Foghorn Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary